Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives $6.23 Average Price Target from Analysts

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have received a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and two have given a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $6.2333.

A number of equities analysts have commented on IRWD shares. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Sunday, May 17th. Zacks Research raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 1st. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, April 27th.

Insider Transactions at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, Director Julie Mchugh sold 21,571 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $3.73, for a total transaction of $80,459.83. Following the transaction, the director directly owned 250,749 shares in the company, valued at approximately $935,293.77. This represents a 7.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 9.30% of the company’s stock.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Krilogy Financial LLC lifted its holdings in Ironwood Pharmaceuticals by 9.8% in the first quarter. Krilogy Financial LLC now owns 33,194 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 2,971 shares during the period. ProShare Advisors LLC raised its position in shares of Ironwood Pharmaceuticals by 9.6% during the 4th quarter. ProShare Advisors LLC now owns 36,315 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 3,170 shares during the last quarter. Integrated Wealth Concepts LLC raised its position in shares of Ironwood Pharmaceuticals by 21.4% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 3,406 shares during the last quarter. DGS Capital Management LLC lifted its stake in shares of Ironwood Pharmaceuticals by 42.8% in the 1st quarter. DGS Capital Management LLC now owns 14,883 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 4,458 shares during the period. Finally, Mercer Global Advisors Inc. ADV lifted its stake in shares of Ironwood Pharmaceuticals by 7.8% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 76,951 shares of the biotechnology company’s stock valued at $259,000 after purchasing an additional 5,598 shares during the period.

Ironwood Pharmaceuticals Price Performance

Shares of NASDAQ:IRWD opened at $4.47 on Friday. The business’s fifty day moving average price is $3.85 and its two-hundred day moving average price is $3.93. Ironwood Pharmaceuticals has a fifty-two week low of $0.67 and a fifty-two week high of $5.78. The stock has a market capitalization of $728.87 million, a price-to-earnings ratio of 7.45 and a beta of 0.20.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Ironwood Pharmaceuticals had a net margin of 28.26% and a negative return on equity of 39.65%. The company had revenue of $106.51 million for the quarter, compared to the consensus estimate of $92.11 million. Research analysts expect that Ironwood Pharmaceuticals will post 1.04 EPS for the current fiscal year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.